Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

L-Carnitine and Meldonium Interaction: Avoid | Peptide Database

Compound Profiles L-Carnitine Amino Acid Derivative | Fatty Acid Transporter Acts as a carrier molecule, shuttling long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system. This is the rate-limiting ste

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

L-Carnitine

Amino Acid Derivative | Fatty Acid Transporter

Acts as a carrier molecule, shuttling long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system. This is the rate-limiting step in fatty acid oxidation for energy production.

Meldonium

Metabolic Modulator | Endurance & Cardioprotection

Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time.

Combined Organ Load

Frequently Asked Questions

Can I take L-Carnitine with Meldonium?

Combining L-Carnitine with Meldonium is not recommended. Meldonium and L-carnitine operate through directly opposing mechanisms. Meldonium works by inhibiting carnitine biosynthesis to reduce fatty acid oxidation, while exogenous L-carnitine supplementation aims to enhance fatty acid transport and oxidation. Co-administration would be pharmacologically contradictory, with each agent undermining the other's mechanism of action. Users should choose one approach or the other based on their goals, not combine them.

Is L-Carnitine and Meldonium safe together?

This combination carries significant risk. Meldonium and L-carnitine operate through directly opposing mechanisms. Meldonium works by inhibiting carnitine biosynthesis to reduce fatty acid oxidation, while exogenous L-carnitine supplementation aims to enhance fatty acid transport and oxidation. Co-administration would be pharmacologically contradictory, with each agent undermining the other's mechanism of action. Users should choose one approach or the other based on their goals, not combine them. Consult a healthcare professional before combining.

What are the interactions between L-Carnitine and Meldonium?

Meldonium and L-carnitine operate through directly opposing mechanisms. Meldonium works by inhibiting carnitine biosynthesis to reduce fatty acid oxidation, while exogenous L-carnitine supplementation aims to enhance fatty acid transport and oxidation. Co-administration would be pharmacologically contradictory, with each agent undermining the other's mechanism of action. Users should choose one approach or the other based on their goals, not combine them. This assessment has 95% confidence and is based on documented research data.

How should I time L-Carnitine and Meldonium?

L-Carnitine has a half-life of ~2-3 hours (injectable) and Meldonium has a half-life of ~4-6 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching RU-58841 — share findings, ask questions, and learn from real experiences RU-58841 is a non-steroidal anti-androgen originally developed by Roussel Uclaf (later Hoechst Marion Roussel) in the 1970s-80s for topical treatment of androgen-dependent conditions including acne and androgenetic alopecia. It works by competitively binding to androgen receptors at the hair follicle, blocking the effects of dihydrotestosterone (DHT) locally without significantly reducing systemic androgen levels. Development was abandoned after Phase II clinical trials, and the compound was never submitted for regulatory approval. Despite this, RU-58841 has developed a substantial following in the hair loss community, where users source it as a raw research chemical and prepare their own topical solutions. Its extremely short systemic half-life means that even if absorbed through the skin, it is rapidly metabolized, limiting systemic anti-androgenic effects. However, the lack of completed clinical trials means its long-term safety profile remains unknown. RU-58841 functions as a competitive antagonist of the androgen receptor (AR). When applied topically to the scalp, it penetrates the skin and binds directly to androgen receptors in dermal papilla cells of hair follicles, preventing dihydrotestosterone (DHT) and testosterone from activating those receptors. This is fundamentally different from 5-alpha reductase inhibitors like finasteride, which reduce DHT production systemically. RU-58841 does not lower DHT or testosterone levels at all; it simply blocks their action at the receptor level in the tissue where it is applied. The compound has a very high binding affinity for the androgen receptor but an extremely short systemic half-life of roughly one hour due to rapid hydrolysis of its amide bond in the bloodstream. This pharmacokinetic profile is intentional: it confines the anti-androgenic activity to the scalp while minimizing the risk of systemic side effects such as sexual dysfunction or hormonal disruption. Animal studies in hamster flank organ and stumptail macaque models demonstrated significant local anti-androgenic effects, including hair regrowth and inhibition of androgen-dependent sebaceous gland activity, without measurable systemic anti-androgenic effects at therapeutic topical doses.

Source: peptide-db.com ↗

Does Cerebrolysin actually work for stroke recovery or is the evidence mixed?

Evidence is mixed. Large meta-analysis of 1,879 stroke patients showed NIHSS (neurological function) superiority, but an independent analysis found no significant improvement in modified Rankin Scale (functional outcomes). Cerebrolysin appears to have early neurological benefits without clear long-term functional recovery advantage.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Standard administration route; allows precise dosing and rapid hormone stimulation. Gonadotropin stimulation 100-200mcg Single dose or 2-3x weekly SubQ Fertility support 0.4-1.0 nmol/kg (50-150mcg) As directed by physician SubQ (KP-54) Sexual function (clinical) 1 nmol/kg/h 75-minute IV infusion IV infusion

Source: peptide-db.com ↗
Side effects

Common Side Effects

Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users Metallic taste in mouth Decreased appetite Flatulence and abdominal distension Loose stools, particularly when initiating therapy or increasing dose

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides